HeartBeam Inc. (NASDAQ: BEAT), a medical technology company focused on cardiac care, announced that the U.S. Food and Drug Administration (FDA) has accepted its HeartBeam System into the Total Product Life Cycle Advisory Program (TAP) Pilot. The acceptance follows the receipt of Breakthrough Device Designation earlier this month and applies to the company's 3D electrocardiogram (ECG) technology being developed to assess potential heart attacks outside traditional medical settings.
The TAP program provides dedicated FDA advisors, expedited regulatory feedback, and access to healthcare providers, patient advocacy groups, and insurers to help accelerate development and patient access. For HeartBeam, this means a more streamlined regulatory pathway as it seeks to expand the indications for its HeartBeam System to include heart attack assessment. The company estimates the heart attack assessment market opportunity at approximately $15 billion within a broader cardiac platform opportunity exceeding $40 billion.
HeartBeam expects to seek FDA alignment on its multicenter pivotal study design in the coming months, with patient enrollment anticipated to begin in the first quarter of 2027. The study is intended to support a future regulatory submission expanding the HeartBeam System's indications to include heart attack assessment. The company is also evaluating eligibility for the Regulatory Alignment for Predictable and Immediate Device (RAPID) coverage pathway, designed to accelerate Medicare access to eligible Breakthrough devices.
The HeartBeam System is not currently cleared for heart attack detection, and TAP participation does not guarantee future FDA authorization or insurance coverage. However, the company's 3D ECG technology received FDA clearance for arrhythmia assessment in December 2024 and the 12-lead ECG synthesis software in December 2025. The company holds over 20 issued patents related to technology enablement.
For investors, the TAP acceptance signals potential acceleration in HeartBeam's path to market for a heart attack detection tool that could be used wherever the patient is, redefining cardiac health management. The ability to collect ECG signals in 3D from three non-coplanar directions and synthesize them into a 12-lead ECG is designed for portable devices, enabling physicians to identify cardiac health trends and acute conditions outside of a medical facility. This could lead to faster triage and reduced healthcare costs. The latest news and updates relating to BEAT are available in the company's newsroom at https://nnw.fm/BEAT, and detailed information on the company's cleared indications for use can be found at https://www.heartbeam.com/indications.
The announcement was distributed via NetworkNewsWire, a specialized communications platform that is part of the Dynamic Brand Portfolio at IBN. NetworkNewsWire provides access to wire solutions through InvestorWire and offers editorial syndication to 5,000+ outlets, among other services. For full terms and disclaimers, visit https://www.NetworkNewsWire.com/Disclaimer.
